CD274 and neoplasm: The immunologic inertia of metastatic lesions [42] and immune privilege mechanism in cold tumor cases [43] count for potential explanations of the low response rate in TNBC, both highlight the critical role of addressing deficient T cell priming in PD-1/PD-L1-refractory cancers.